They ultimately proposed the connexin 43 hemichannel blockers (carbenoxolone, Gap19 and Gap26) and PKC inhibitors (blocking the phosphorylation of Cx43 hemichannels) as potential therapeutic targets for AF [103]. This evidence concerns the gene GJA1 and atrial fibrillation.